Rezolute (RZLT) Interest Coverage Ratio (2012 - 2026)
Rezolute (RZLT) posted Interest Coverage Ratio of 5.11 for Q1 2026, up 47.28% sequentially from 9.69 in Q4 2025, and down 7.14% YoY from 5.5 in Q1 2025.
Rezolute (RZLT) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Rezolute has reported Interest Coverage Ratio for 15 years, with the latest figure at 5.11 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 7.14% year-over-year to 5.11 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25.66 (down 39.71% YoY) and the FY2025 annual result came in at 0.89, up 81.58% from the prior year.
- Interest Coverage Ratio rose to 5.11 in Q1 2026 per RZLT's latest filing, from 9.69 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.27 in Q3 2025 and troughed at 136.77 in Q2 2025.
- A 5-year average of 35.16 and a median of 15.36 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio soared 97.97% in 2024, then plunged 989.09% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 24.07 in 2022, then sank by 82.46% to 43.91 in 2023, then jumped by 97.97% to 0.89 in 2024, then slumped by 989.09% to 9.69 in 2025, then jumped by 47.28% to 5.11 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 5.11, 9.69, and 0.27 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | -5.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.11 |
| Dec 31, 2025 | -9.69 |
| Sep 30, 2025 | -0.27 |
| Jun 30, 2025 | -136.77 |
| Mar 31, 2025 | -4.77 |
| Dec 31, 2024 | -0.89 |
| Sep 30, 2024 | -0.88 |
| Jun 30, 2024 | -125.55 |
| Mar 31, 2024 | -4.50 |
| Dec 31, 2023 | -43.91 |
| Sep 30, 2023 | -23.89 |
| Jun 30, 2023 | -111.23 |
| Mar 31, 2023 | -5.85 |
| Dec 31, 2022 | -24.07 |
| Sep 30, 2022 | -61.19 |
| Jun 30, 2022 | -23.74 |
| Mar 31, 2022 | -15.36 |
| Dec 31, 2021 | -17.36 |
| Sep 30, 2021 | -10.91 |
| Jun 30, 2021 | -276.50 |